Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVER-AD long-term extension of amlitelimab in moderate-to-severe atopic dermatitis
MOH_2025-04-08_014025Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of amlitelimab in atopic dermatitis (AD) (2 arms), sponsored by Sanofi. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2025-04-08_014025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-08_014025.